Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16-specific immune response following HPV16 E6/E7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia grade III

Next Previous
X
Search
Trial Profile

Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16-specific immune response following HPV16 E6/E7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia grade III

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peltopepimut-S (Primary) ; Imiquimod
  • Indications Human papillomavirus infections; Vulvar intraepithelial neoplasia
  • Focus Pharmacodynamics; Proof of concept

    • Most Recent Events

    • 14 Apr 2016 Results published in the journal Clinical Cancer Research, according to an ISA Pharmaceuticals media release.
    • 24 Feb 2014 According to an ISA Pharmaceuticals media release, the status of this trial is completed.
    • 01 Jan 2014 Status changed from recruiting to suspended.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top